Characteristics of bortezomib- and thalidomide-induced peripheral neuropathy. - Wikidata - awgldk - TriplyDB

Characteristics of bortezomib- and thalidomide-induced peripheral neuropathy.

Characteristics of bortezomib- and thalidomide-induced peripheral neuropathy.

http://www.wikidata.org/entity/Q37090630

about

Current and emerging treatment options for patients with relapsed myeloma Neuropathic cancer pain: What we are dealing with? How to manage it?Bortezomib-induced painful peripheral neuropathy: an electrophysiological, behavioral, morphological and mechanistic study in the mouse The choice of regimens based on bortezomib for patients with newly diagnosed multiple myeloma Chemotherapy-induced neuropathies-a growing problem for patients and health care providers Phase I trial of fludarabine, bortezomib and rituximab for relapsed and refractory indolent and mantle cell non-Hodgkin lymphoma Peripheral neuropathy and new treatments for multiple myeloma: background and practical recommendations.Pain in cancer survivors Schwann cell autophagy induced by SAHA, 17-AAG, or clonazepam can reduce bortezomib-induced peripheral neuropathy Sensitization of capsaicin and icilin responses in oxaliplatin treated adult rat DRG neurons.Sleep measured by polysomnography in patients receiving high-dose chemotherapy for multiple myeloma prior to stem cell transplantation.Acupuncture treatment for bortezomib-induced peripheral neuropathy: a case report Bortezomib and thalidomide, a steroid free regimen in newly diagnosed patients with multiple myeloma.Peripheral neuropathies from chemotherapeutics and targeted agents: diagnosis, treatment, and prevention.The rise, fall and subsequent triumph of thalidomide: lessons learned in drug development.Subclinical pretreatment sensory deficits appear to predict the development of pain and numbness in patients with multiple myeloma undergoing chemotherapy.Anti-nociceptive effect of a conjugate of substance P and light chain of botulinum neurotoxin type A Long-Term Effects, Pathophysiological Mechanisms, and Risk Factors of Chemotherapy-Induced Peripheral Neuropathies: A Comprehensive Literature Review.Pain management in multiple myeloma.Peripheral neuropathy during bortezomib treatment of multiple myeloma: a review of recent studies.Pain in malignant hematology.TRAF6 activation in multiple myeloma: a potential therapeutic target A case of peripheral nerve microvasculitis associated with multiple myeloma and bortezomib treatment.Thalidomide-analogue biology: immunological, molecular and epigenetic targets in cancer therapy.Drug-induced peripheral neuropathy.Chemotherapy-induced polyneuropathy: major agents and assessment by questionnaires.Mechanism-based treatment for chemotherapy-induced peripheral neuropathic pain.Therapy-related peripheral neuropathy in multiple myeloma patients.A comparison of bortezomib, cyclophosphamide, and dexamethasone (Vel-CD) chemotherapy without and with thalidomide (Vel-CTD) for the treatment of relapsed or refractory multiple myeloma.Kinesin-5 Blocker Monastrol Protects Against Bortezomib-Induced Peripheral Neurotoxicity.Controlled-release oxycodone for the treatment of bortezomib-induced neuropathic pain in patients with multiple myeloma.Chemotherapy-induced peripheral neuropathy: A current review.Depletion of nerve growth factor in chemotherapy-induced peripheral neuropathy associated with hematologic malignancies Pathological adaptive responses of Schwann cells to endoplasmic reticulum stress in bortezomib-induced peripheral neuropathy.Lenalidomide in patients with chemotherapy-induced polyneuropathy and relapsed or refractory multiple myeloma: results from a single-centre prospective study.Improvement of Painful Bortezomib-Induced Peripheral Neuropathy Following Acupuncture Treatment in a Case Series of Multiple Myeloma Patients.Prediction of peripheral neuropathy in multiple myeloma patients receiving bortezomib and thalidomide: a genetic study based on a single nucleotide polymorphism array.Paraproteinemic neuropathy.Bortezomib- and thalidomide-induced peripheral neuropathy in multiple myeloma: clinical and molecular analyses of a phase 3 study Impact of dose modification on intravenous bortezomib-induced peripheral neuropathy in multiple myeloma patients

P2860

Q26830878-00A1A491-EBE6-4356-9790-E6C4F837B64E Q26998945-8C0DF311-AAC6-47FA-AA01-6E6B5E58BC72 Q28533426-3D2218CC-26B6-4E56-AEF4-E128B3D575DB Q28539605-BDDEC8BB-417F-42DA-A3D5-0447AB0AC992 Q28818565-14BF968F-2464-4EF5-A52E-DDC9B77704D3 Q33385670-2460F25D-D5C5-40FF-9223-4EF054F89668 Q33632270-3D7E8948-E19B-456A-BCDA-35B8CF9C64AE Q33650576-C235B79C-919C-4117-9497-5ECF36D10EB5 Q34344053-0DF9A508-4ED1-4CD2-99CA-705B2ACC2CC4 Q34412078-1D3199DD-D87B-4078-BFE5-1AF36098E6D9 Q35072925-D7F2A8DB-BF83-4C39-AD27-11354376701C Q35428713-A5D3C43B-BAEC-46E4-BB9B-F4F2E0A20D07 Q36141664-944F7AFC-9E69-4193-956E-304FB255813B Q36344699-C57B8EDD-F94F-4523-AB14-9204CEC03024 Q36612613-D87E377F-C650-496C-AEF5-D410203BBD1A Q36893299-4A7B275E-02E6-4E86-A825-8864F061A9EA Q37255758-F870B608-0A44-46FF-A5E5-D5E237D6DA0D Q37662576-CFA10994-DBD4-42B1-9207-767F01B8CD26 Q37705421-CCE98857-45E6-406B-B38C-E56E08D38C48 Q37760210-A6456352-F9CA-4B49-B592-ACF0F88619DD Q37842353-BFC8327F-8878-43B6-97BD-B7FAD7AD14D9 Q37996112-71F2C79B-1788-48DC-8828-BE6E2E727D7B Q38066137-6791F45C-4B91-4B4F-A339-70FC5095460F Q38074017-7FA09257-7685-40D3-B9AE-EC304D68D668 Q38208565-C5230F67-EE53-49D1-A507-C94428E19F3F Q38209390-E9CD8022-8265-442A-980F-30D13B9F8A2D Q38264622-06EA6C27-CB98-4753-9C3C-CC30C9DE9B6F Q38268525-457C4935-EF4E-49BC-AEC3-4E2D41F3A4B5 Q38465618-6FFC2DDF-5D88-4688-BBFA-32790C66688D Q38726608-39999E3F-CD77-4B11-B2CC-FC07AAD72E4E Q39246290-D3D72A91-3942-464A-A184-5FFEA202939F Q39293928-6A5F9999-AFB2-459F-A5D5-F7AAA549C080 Q41475920-EA21320C-64AA-4271-953C-7FFFE2858933 Q42911212-93F5790F-5867-4182-B49C-B3FCA8691E85 Q46501555-6F8CA64D-0C31-4AC3-ABBB-16C927804E80 Q46755854-BBBBEF7E-0682-459B-AB32-782B10669690 Q48682753-A5AB81EE-4B62-42CC-9479-8DBA5BB34204 Q53791232-25DD740D-3836-45AB-9776-0AECFA7EB1F6 Q56971945-F55CF358-2171-47AC-A4A4-0F7617E323B7 Q57222376-85E9F63E-4513-47D4-89C2-7B3CE208BF68

P2860

Characteristics of bortezomib- and thalidomide-induced peripheral neuropathy.

http://www.wikidata.org/entity/Q37090630

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on December 2008

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Characteristics of bortezomib- and thalidomide-induced peripheral neuropathy.

@en

Characteristics of bortezomib- and thalidomide-induced peripheral neuropathy.

@nl

type

label

Characteristics of bortezomib- and thalidomide-induced peripheral neuropathy.

@en

Characteristics of bortezomib- and thalidomide-induced peripheral neuropathy.

@nl

prefLabel

Characteristics of bortezomib- and thalidomide-induced peripheral neuropathy.

@en

Characteristics of bortezomib- and thalidomide-induced peripheral neuropathy.

@nl

P1433

Q37090630-CBC51535-6D25-450F-9884-C50F81BE728E

P1476

Q37090630-E1C1B107-8AE5-43FB-96DE-335F7170F5AA

P2093

Q37090630-10DE7591-59E6-4C4D-8E14-528A78347E15

Q37090630-2465BF1B-A70B-47BB-B813-D6C1C6ED2E59

Q37090630-3CF196BC-68B8-40D2-B715-4F483F122A01

Q37090630-425FFBF0-815C-472F-86CA-B237EBC5601D

Q37090630-8F684FE1-E259-45CD-8EE5-0417AE45A489

P2860

Q37090630-0FC9A5C2-3CBA-4BD9-AA9D-9C8B59A65C71

Q37090630-130B849D-25E8-41D3-BE91-613B81FD44BC

Q37090630-18EC8A94-1B13-4A3A-A9FD-7679FD6AB1A6

Q37090630-194231A3-3B1C-42D3-BE0E-409A6936D1FB

Q37090630-2BA32B59-A807-49D6-9CE4-01C9B7C9DB97

Q37090630-31AC9BCB-CC42-4E56-8787-189A744F9713

Q37090630-352FA5F7-F2A2-4105-99D1-3D4F31F60DE0

Q37090630-52D71288-39DB-4D4C-B278-167A063A201F

Q37090630-591BC1FB-CCAA-4308-8062-A1A7331787A5

Q37090630-62EE5B68-3371-40BB-A603-C82BA580B5E5

P304

Q37090630-0CC680FB-7F53-4F29-A70C-69D3B6151DA7

P31

Q37090630-5BC3D1D3-679B-479A-9B24-4006FBBEA174

P356

Q37090630-8709DCEA-4563-4E20-8C73-6B7A49965647

P433

Q37090630-4D19E9BD-6885-41B6-8A09-1AB1C1702763

P478

Q37090630-EAB79BE3-C3B5-47AA-B23F-ECED3698B895

P577

Q37090630-9176347F-0D6F-498C-855B-040AF0756C91

P5875

Q37090630-72BA7624-0910-442D-8E7C-7E64D18A54DB

P698

Q37090630-FF6BDEBB-BB5C-482A-A99A-C7CCAC49FF04

P921

Q37090630-D3A586AC-DC52-4D03-BB60-1918D41A62A2

P932

Q37090630-FE986857-94CD-4E98-A67A-88AE443B6954

P356

J.1529-8027.2008.00193.X

P1433

Journal of the Peripheral Nervous System

P1476

Characteristics of bortezomib- and thalidomide-induced peripheral neuropathy.

@en

P2093

Anna Ferguson

http://www.w3.org/2001/XMLSchema#string

David R Cornblath

http://www.w3.org/2001/XMLSchema#string

Ivan Borrello

http://www.w3.org/2001/XMLSchema#string

Michael Polydefkis

http://www.w3.org/2001/XMLSchema#string

Vinay Chaudhry

http://www.w3.org/2001/XMLSchema#string

P2860

A phase 2 study of bortezomib in relapsed, refractory myeloma.

Velcade: U.S. FDA approval for the treatment of multiple myeloma progressing on prior therapy.

A multicenter retrospective analysis of adverse events in Korean patients using bortezomib for multiple myeloma.

Bortezomib in combination with intermediate-dose dexamethasone and continuous low-dose oral cyclophosphamide for relapsed multiple myeloma.

Phase II PETHEMA trial of alternating bortezomib and dexamethasone as induction regimen before autologous stem-cell transplantation in younger patients with multiple myeloma: efficacy and clinical implications of tumor response kinetics.

Thalidomide: 40 years on.

Thalidomide: emerging role in cancer medicine.

Bortezomib plus dexamethasone as induction treatment prior to autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: results of an IFM phase II study.

Neurotoxicity of bortezomib therapy in multiple myeloma: a single-center experience and review of the literature.

Bortezomib for the treatment of mantle cell lymphoma.

P304

275-282

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/J.1529-8027.2008.00193.X

http://www.w3.org/2001/XMLSchema#string

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

13

http://www.w3.org/2001/XMLSchema#string

P577

2008-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

23976271

http://www.w3.org/2001/XMLSchema#string

P698

19192067

http://www.w3.org/2001/XMLSchema#string

P921

P932

3741683

http://www.w3.org/2001/XMLSchema#string